 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | KRM-81 / RespireRx
Journal: Comparative anticonvulsant activity of the GABAkine KRM-II-81 and a deuterated analog. (Pubmed Central) - May 15, 2023
Oral administration of 100?mg/kg of either KRM-II-81 or D5-KRM-II-81 was significantly less disruptive of sensorimotor function in mice than diazepam (5?mg/kg, p.o.). The present report documents that D5-KRM-II-81 represents another in this series of imidazodiazepines with anticonvulsant activity at doses that do not impair sensorimotor function.
- KRM-81 / RespireRx
Synthesis, metabolism, pharmacokinetics, and anticonvulsant activity of a deuterated analog of the α2/3-selective GABAkine KRM-II-81 | Poster Board #3375 (Hall F2 (McCormick Place Convention Center)) - Aug 9, 2022 - Abstract #ACSFall2022ACS_Fall_3416;
D5-KRM-II-81, like KRM-II-81, significantly prevented seizures induced by pentylenetetrazol when given orally despite its lack of augmented exposure. These findings of this new orally active anticonvulsant GABAkine, D5-KRM-II-81 will be presented.
- || KRM-81 / RespireRx
PK/PD data, Journal: Metabolism, pharmacokinetics, and anticonvulsant activity of a deuterated analog of the α2/3-selective GABAkine KRM-II-81. (Pubmed Central) - Apr 14, 2022
Despite its lack of augmented exposure, D5-KRM-II-81, like KRM-II-81, significantly prevented seizures induced by pentylenetetrazol when given orally. The present findings introduce a new orally active anticonvulsant GABAkine, D5-KRM-II-81.